Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LPO | P22079 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419709 | 0.73 | KMT2A (0.50) | KCNH2KMT2ALPO | |
| SCHEMBL15314833 | 0.71 | KMT2A (0.36) | KCNH2KMT2ALPO | |
| SCHEMBL27854351 | 0.71 | KCNH2 (0.33) | KCNH2KMT2ALPO | |
| SCHEMBL18472183 | 0.71 | KCNH2 (0.33) | KCNH2KMT2ALPO | |
| Hydrochloric Acid SCHEMBL16540240 | 0.71 | KMT2A (0.48) | KCNH2KMT2ALPO | |
| SCHEMBL422085 | 0.71 | KCNH2 (0.33) | KCNH2KMT2ALPO | |
| Hydrochloric Acid SCHEMBL21110936 | 0.70 | KCNH2 (0.32) | KCNH2KMT2A | |
| SCHEMBL18235319 | 0.68 | KCNH2 (0.31) | KCNH2KMT2A | |
| SCHEMBL464563 | 0.68 | KCNH2 (0.43) | KCNH2KMT2A | |
| SCHEMBL18330879 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| US-10799504-B2 | Heterocyclic compounds and uses as anticancer agents | ACEA Therapeutics, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
| CN-101511796-B | Imidazole derivatives | KYOWA HAKKO KOGYO KK | 2012-05-09 | — | — | CN | disclosed |
| CN-101511796-A | Imidazole derivative | KYOWA HAKKO KOGYO KK (JP) | 2009-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | KCNH2 3090/4885KMT2A 2428/4885LPO 4874/4885 |
| US-10799504-B2 | Heterocyclic compounds and uses as anticancer agents | ERBB2, EGFR, ERBB3 | KCNH2 4795/4885KMT2A 2218/4885LPO 4545/4885 |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3B | KCNH2 2785/4885KMT2A 2381/4885LPO 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.